Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. Coli Publisher Pubmed



Hashemzaei M1 ; Ghoshoon MB1 ; Jamshidi M1 ; Moradbeygi F1 ; Hashemzehi A2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  2. 2. Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Recent Patents on Biotechnology Published:2024


Abstract

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder determined by immune-mediated platelet demolition and reduction of platelet production. Romiplostim is a new thrombopoiesis motivating peptibody that binds and stimulates the human throm-bopoietin receptor the patent of which was registered in 2008. It is used to treat thrombocy-topenia in patients with chronic immune thrombocytopenic purpura. Romiplostim is a 60 kDa peptibody designed to inhibit cross-reacting immune responses. It consists of four high-affinity TPO-receptor binding domains for the Mpl receptor and one human IgG1 Fc domain. Escherichia coli is a good host for the fabrication of recombinant proteins such as romiplostim. The expression of a gene intended in E. coli is dependent on many factors such as a protein’s inherent ability to fold, mRNA’s secondary structure, its solubility, its toxicity preferential codon use, and its need for post-translational modification (PTM). This review focuses on the structure, function, mechanism of action, and expressive approach to romiplostim in E. coli. © 2024 Bentham Science Publishers.